(NYSE Amex Equities : CVM)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
AMGNAmgen, Inc. 1.22%246.481.5%$948.65m
MRNAModerna, Inc. -0.65%141.270.0%$800.66m
REGNRegeneron Pharmaceuticals, Inc. 1.68%604.412.6%$520.64m
VRTXVertex Pharmaceuticals, Inc. 1.41%280.051.9%$508.82m
GILDGilead Sciences, Inc. 0.08%62.261.0%$508.16m
NVAXNovavax, Inc. 0.73%51.4375.7%$420.16m
ILMNIllumina, Inc. -1.55%184.543.3%$352.02m
BIIBBiogen, Inc. 0.93%204.401.8%$244.44m
SNSSSunesis Pharmaceuticals, Inc. 3.14%3.450.7%$241.17m
BNTXBioNTech SE 0.52%140.550.0%$167.76m
CRSPCRISPR Therapeutics AG -1.50%62.330.6%$167.34m
BMRNBioMarin Pharmaceutical, Inc. 0.16%83.284.2%$123.71m
EXASEXACT Sciences Corp. -1.78%40.3817.7%$97.73m
TECHBio-Techne Corp. -0.69%343.644.5%$92.58m
IOVAIovance Biotherapeutics, Inc. -4.28%10.510.0%$91.56m

Company Profile

CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.